Evidence map›Paper›PMID 33742242›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2021

Functional impairment, symptom severity, and overall quality of life in patients with advanced lung or colorectal cancer in six European countries: baseline findings from the ACTION study.

Mariëtte N Verkissen, Aline De Vleminck, Mogens Groenvold, Lea J Jabbarian, Francesco Bulli, Wilfried Cools, Johannes J M van Delden, Urška Lunder, Guido Miccinesi, Sheila A Payne and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mariëtte N VerkissenVrije Universiteit Brussel (VUB) & Ghent University, End-of-Life Care Research Group, Brussels, Belgium. mariette.verkissen@vub.be.ORCID http://orcid.org/0000-0002-7797-5290
Aline De VleminckVrije Universiteit Brussel (VUB) & Ghent University, End-of-Life Care Research Group, Brussels, Belgium.
Mogens GroenvoldUniversity of Copenhagen, Department of Geriatrics and Palliative Medicine, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
Lea J JabbarianErasmus University Medical Center, Department of Public Health, Rotterdam, Netherlands.
Francesco BulliOncological Network, Prevention and Research Institute (ISPRO), Clinical Epidemiology, Florence, Italy.
Wilfried CoolsVrije Universiteit Brussel (VUB), Interfaculty Center Data Processing and Statistics, Brussels, Belgium.
Johannes J M van DeldenUniversity Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, Netherlands.
Urška LunderUniversity Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.
Guido MiccinesiOncological Network, Prevention and Research Institute (ISPRO), Clinical Epidemiology, Florence, Italy.
Sheila A PayneLancaster University, International Observatory on End of Life Care, Division of Health Research, Lancaster, United Kingdom.
Kristian PollockUniversity of Nottingham, School of Health Sciences, Nottingham, United Kingdom.
Judith A C RietjensErasmus University Medical Center, Department of Public Health, Rotterdam, Netherlands.
Luc DeliensVrije Universiteit Brussel (VUB) & Ghent University, End-of-Life Care Research Group, Brussels, Belgium.

Funding

European Union's Seventh Framework Programme for Research and Technological Development (FP7) 6025410-2
6 · The paper itself

Abstract

backgroundPeople with advanced cancer often suffer from various symptoms, which can arise from the cancer itself and its treatment, the illness experience, and/or co-morbid conditions. Important patient-reported outcomes such as functional status, symptom severity, and quality of life (QoL) might differ between countries, as countries vary with regard to contextual factors such as their healthcare system. PURPOSE: To assess self-reported emotional functioning, physical functioning, symptoms, and overall QoL in patients with advanced lung or colorectal cancer from six European countries, particularly in relation to their country of residence.

methodsWe used baseline patient data from the ACTION trial, including socio-demographic and clinical data as well as patient-reported data regarding functioning, symptoms, and overall QoL (EORTC QLQ-C15-PAL).

resultsData from 1117 patients (55% lung cancer stage III/IV, 45% colorectal cancer stage IV) were used. The highest (worst) average symptom score was found for fatigue. We found similarities but also important differences in the outcomes across countries. The best scores (the highest for emotional functioning and QoL, the lowest for symptoms) were reported by Dutch and Danish patients. Belgian patients reported relatively low emotional functioning.

conclusionThe optimization of functioning, symptom relief, and overall QoL should be important objectives of healthcare professionals who take care of patients with advanced cancer. There are similarities, but also substantial differences across countries in functional status, symptoms, and overall QoL. Policymakers should take these differences into account and invest in offering health care catered to the needs of their population.

Indexed as

Colorectal NeoplasmsLung NeoplasmsHumansLungPalliative CareQuality of LifeSurveys and QuestionnairesAdvanced cancerColorectal cancerFunctional statusLung cancerPalliative careQuality of lifeSymptoms

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.